Table 2.
Cytotoxicity of the CYB-L10 in drug-resistant human cancer cell lines.
| Cpd. | GI50 ± SD (μM)a |
Resistance ratiob | |
|---|---|---|---|
| Parental cell line | Resistant subline | ||
| HCT116 | HCT116-siTop1 | ||
| CYB-L10 | 0.027 ± 0.024 | 0.19 ± 0.092 | 7.0 |
| CPT | 0.009 ± 0.001 | 0.075 ± 0.014 | 8.3 |
| DU-145 | RC0.1 | ||
| CYB-L10 | 0.016 ± 0.010 | 0.65 ± 0.010 | 40.6 |
| CPT | 0.019 ± 0.009 | 7.53 ± 1.88 | 396.3 |
| MCF-7 | MCF-7/ADR | ||
| CYB-L10 | 0.091 ± 1.33 | 0.60 ± 0.21 | 6.6 |
| DOX | 0.15 ± 0.003 | 11.67 ± 1.94 | 77.8 |
| HepG2 | HepG2/ADR | ||
| CYB-L10 | 0.065 ± 0.030 | 0.74 ± 0.24 | 11.4 |
| DOX | 0.19 ± 0.048 | 9.04 ± 0.14 | 47.6 |
a
GI50 values (means ± SD) were defined as the concentrations of compounds that resulted in 50% cell growth inhibition, and obtained from MTT assay. Every experiment was repeated at least three times.
b
Resistance ratio was calculated by dividing the GI50 of the mutant cell line by the GI50 of the corresponding parental cell line.